

Date: April 07, 2025

To,
Sr. General Manager
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400001

BSE Scrip Code: 544319

To,
Sr. General Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

NSE Symbol: SENORES

Dear Sir/Madam,

Sub: Submission of Reconciliation of Share Capital Audit Report for the quarter ended March 31, 2025 under Regulation 76 of the SEBI (Depositories and Participants) Regulations, 2018.

In compliance with Regulation 76 of the SEBI (Depositories and Participants) Regulations, 2018, please find enclosed herewith Reconciliation of Share Capital Audit Report, dated April 04, 2025 duly signed and issued by Mr. Tapan Shah, Company Secretary in Practice, for the quarter ended on March 31, 2025.

Kindly take the same on your records.

Thanking you.

For Senores Pharmaceuticals Limited

Vinay Kumar Mishra
Company Secretary and Compliance Officer
ICSI Membership No.: F11464

Encl.: As mentioned above

Senores Pharmaceuticals Limited

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: info@senorespharma.com

W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263

To,
 The Board of Directors,
SENORES PHARMACEUTICALS LIMITED,
 1101 to 1103, 11th floor, South Tower,
 ONE 42 Opp. Jayantilal Park, Ambali Bopal Road,
 Ahmedabad, Ahmedabad, Gujarat, India, 380054

RECONCILIATION OF SHARE CAPITAL AUDIT REPORT

CIN : L24290GJ2017PLC100263
 Authorised Capital : Rs. 59,00,00,000

I have examined the Register of Members, beneficiary details given by the Depositories and other records / documents maintained by M/s. **SENORES PHARMACEUTICALS LIMITED**, having its Registered Office at 1101 to 1103, 11th floor, South Tower, ONE 42 Opp. Jayantilal Park, Ambali Bopal Road, Ahmedabad, Gujarat, India, 380054 for issuing Certificate, in accordance with Circular D&CC/FITTC/CIR-16/2002 dated December 31, 2002 issued by Securities and Exchange Board of India (SEBI). To the best of my knowledge and according to the information and explanation given to me and as per the record received through mail and examined by me, I certify that for the quarter ended 31st March, 2025, the details of position of Company's Capital Structure, its Equity shares position with NSDL, CDSL and Physical, Demat carried out and pending Demat status and other details are as under:

1	For Quarter Ended	31/03/2025
2	ISIN	INE0RB801010
3	Face Value	Rs. 10/- per Share
4	Name of the Company	SENORES PHARMACEUTICALS LIMITED
5	Registered Office Address	1101 to 1103, 11th floor, South Tower, ONE 42 Opp. Jayantilal Park, Ambali Bopal Road, Ahmedabad, Ahmedabad, Gujarat, India, 380054.
6	Correspondence Address	-- Same as above --
7	Telephone & Fax Nos.	Tel. 079- 29999857
8	Email Address	cs@senorespharma.com
9	Name of the Stock Exchanges where the Company's Securities are listed with scrip code	1. The National Stock Exchange of India Limited.(Symbol: SENORES) 2. BSE Limited (Scrip Code: 544319)
10	Issued Equity Share Capital	No. of Shares 4,60,53,588



11	Listed Equity Capital (as per company records)	4,60,53,588					
		No. of shares		% of issued Capital			
12	Held in dematerialized form in NSDL	2,59,56,182		56.36			
13	Held in dematerialized form in CDSL	2,00,97,406		43.64			
14	Physical	0		0.00			
15	Total No. of Shares (12+13+14)	4,60,53,588		100.00			
16	Reason for difference, if any, between (10&11),(11 & 15)	N.A.					
17	Certifying details of changes in share capital during the quarter under consideration as per Table below :						
Particulars	No. of Shares	Applied/ not Applied for Listing	Listed on Stock Exchanges (Specify Names)	Whether intimated to CDSL	Whether intimate d to NSDL	In-principle Approval Pending for SE (Specify Names)	
NA	NA	NA	NA	NA	NA	NA	
18	Register of Members is updated (YES/NO) if not, updated up to which date			Yes			
19	Reference of previous quarter with regards to excess dematerialized shares, if any			-- N.A. --			
20	Has the company resolved the matter mentioned in point no. 19 above in the current quarter? If not, reason why?			-- N.A. --			
21	Mentioned the total no. of requests, confirmed after 21 days and the total no. of requests pending beyond 21 days(in both cases, from the date of DRN & confirmed by the Registrar is taken), with the reasons for delay :						
Total No. of demat requests			No. of requests		No. of shares		Reasons for delay
			NSDL	CDSL	NSDL	CDSL	
Confirmed after 21 days			--	--	--	--	N.A.
Pending for more than 21 Days			--	--	--	--	
22	Name, Telephone & Fax No. of Compliance Officer of the Co.			Mr. Vinay Kumar Mishra, Company Secretary and Compliance Officer. Tel.: +91-79-29999857 E-mail: cs@senorespharma.com			



23	Name, Address, Tel. & Fax No. of the Company Secretary in whole-time practice	Mr. Tapan Shah (CP No.2839) 816-818, Anand Mangal-3, Nr. Doctor House, Ellisbridge, Ahmedabad-6 Tel.: 40024320 E-Mail: info@tapanshah.in
24	Appointment of Common Agency for Share Registry Work (Name & Address)	MUFG Intime India Pvt. Ltd.(Formerly known as “Link Intime India Private Limited”) C 101, Embassy 247, L.B, S. Marg, Vikhroli (West), Mumbai- 400083, Maharashtra, India. Tel-022-49186270/ 49186000, Fax-022-49186060, E-mail: rnt.helpdesk@inmpms.mufig.com
25	Any other detail that the Co. Secretary may like to provide (e.g. BIFR Co., delisting from SE, Company changed its name etc.)	--

Place: Ahmedabad.
Date: 04.04.2025

TAPAN
RAJNIKANT
Signature: SHAH
Name of Company Secretary: TAPAN SHAH
C. P. Number: 2839
UDIN: F004476G000030678

Digitally signed by
TAPAN RAJNIKANT
SHAH
Date: 2025.04.07
14:37:44 +05'30'

Note:

Above report was prepared based on the softcopy of the papers/ report/ documents provided by the Share Registry of the Company, i.e. MUFG Intime India Private Ltd.(Formerly known as “Link Intime India Private Limited”)

